S&P 500 Stocks: These 2 Lagging Retailers Become Leaders In December

Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating research into psychedelic-assisted therapies and expanding patient access for certain serious mental health conditions, including post-traumatic stress disorder (PTSD) and treatment-resistant depression. The executive order, signed by Trump on Saturday, directs the US Food and Drug Administration (FDA) Commissioner to prioritize review pathways for psychedelic drugs that have received Breakthrough Therapy designation for serious mental illnesses and meet criteria under a national voucher program designed to speed regulatory review.

The cannabis industry has undergone many breakthrough points of innovation. With cultivators and legal operators keeping the focus on the future and working with its political landscape. Cannabis is a profitable crop similar to tobacco or corn.

Investors are uncertain about tech companies because of AI spending, not the Iran war. Four major hyperscalers spent $410.2 billion last year, and there’s concern about whether the returns will justify that kind of investment.